Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.6901
+0.01662.46%
Post-market: 0.6800-0.0101-1.46%19:55 EDT
Volume:1.79M
Turnover:1.23M
Market Cap:9.75M
PE:-0.15
High:0.7127
Open:0.6900
Low:0.6443
Close:0.6735
Loading ...

Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating

TIPRANKS
·
13 hours ago

Moleculin Biotech Hosts Key Opinion Leaders Event

TIPRANKS
·
Yesterday

Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data

TIPRANKS
·
Yesterday

Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses

MT Newswires Live
·
Yesterday

Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results

TIPRANKS
·
04 Jun

Moleculin Biotech Inc - Clinical Benefit Rate of 59.4% in Annamycin Trial

THOMSON REUTERS
·
04 Jun

Moleculin Reports Positive Topline Efficacy Results From U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (Mb-107)

THOMSON REUTERS
·
04 Jun

Moleculin Biotech files to sell 10.99M shares of common stock, warrants

TIPRANKS
·
03 Jun

Moleculin Biotech Faces Nasdaq Non-Compliance Notice

TIPRANKS
·
24 May

Moleculin Biotech Inc. Faces Nasdaq Listing Rule Violation, Granted 45 Days to Submit Compliance Plan

Reuters
·
24 May

Moleculin Biotech’s Growth Potential Highlighted by Phase 3 MIRACLE Trial and Strategic Advancements

TIPRANKS
·
15 May

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Moleculin Biotech Reports Q1 2025 Financials: R&D Expenses Decrease by $0.9M, G&A Expenses Slightly Increase

Reuters
·
14 May

Moleculin Biotech - Qtrly Loss per Share $0.69

THOMSON REUTERS
·
14 May

Moleculin Biotech Q1 EPS $(0.69) Beats $(0.83) Estimate

Benzinga
·
14 May

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
13 May

Moleculin Biotech’s Annamycin Trial Approved by EMA

TIPRANKS
·
12 May

Moleculin Biotech Cancels Special Stockholders Meeting

TIPRANKS
·
10 May

Moleculin Biotech Inc expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
06 May

Moleculin Biotech Inc - Phase 3 Miracle Trial of Annamycin Interim Data Expected in Second Half of 2025

THOMSON REUTERS
·
06 May